unknown by unknown
expression was conducted at the protein level to attempt to explain the 
differential responsiveness of these cell lines to IL-8. IP-Western analysis 
revealed that CXCR1 expression is higher than that of CXCR2 in both cell 
lines. Flow cytometry and immunocytochemistry demonstrated detectable 
CXCR1 and CXCR2 cell surface receptor expression in PC3 cells, but also 
revealed that CXCR1 and CXCR2 are predominantly localised to distinct foci 
within the cytoplasm of PC3 cells and are almost exclusively localised to 
intracellular compartments of the PNT1-A cells. ELISA analysis has revealed 
that PNT1A cells exhibit a 5-7 fold increase in IL-8 secretion relative to PC3 
cells suggesting that the poor growth response of PNT1A cells to IL-8 may 
reflect their elevated IL-8 production and thus the marked desensitisation of 
the receptors. Our work to date has demonstrated all of the essential features 
of an autocrine IL-8 loop in these prostate cell lines: IL-8 secretion, 
expression and localisation of the IL-8 receptors and in the case of PC3 cells, 
a growth response to the agonist. Ongoing experiments are focused on 
blocking the signalling capacity of endogenous and exogenous IL-8 via 
CXCR1 and CXCR2 using specific antibodies, to identify which IL-8 
receptor  is coupled to the growth-promoting pathway.  
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MELANOMA CELL ATTACHMENT, INVASION AND INTEGRIN 
EXPRESSION IS UPREGULATED BY THE PROINFLAMMATORY 
CYTOKINE    TNF-  AND SUPPRESSED BY THE ANTI-
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Aim: Do proinflammatory cytokines involved in wound healing promote 
melanoma invasion? This is important from both a biological and a clinical 
point of view as they can potentially affect local tumour recurrence. The 
purpose of this study was to examine in vitro the effects of the 
proinflammatory cytokine TNF-  and the anti-inflammatory peptide  -MSH 
on attachment, invasion and integrin expression in a human melanoma cell 
line.  
Materials and methods: The human cutaneous melanoma cell line HBL, 
human recombinant TNF-  and  -MSH were used to examine the effects of 
TNF-  and  -MSH on cell attachment (at 24 h), invasion through fibronectin 
coated micropore membranes (20 h) and integrin expression (detected by 
Western immunoblotting) measured at 24 h. 
Results: 24 h exposure to TNF-  enhanced cell attachment to tissue culture 
plastic, collagen I and collagen IV (table shows the results of tissue culture 
plastic), increased the invasion of melanoma cells through fibronectin and 
upregulated the expression of integrin subunits  3,  4 and  1. Exposure of 
cells to  -MSH significantly reduced cell attachment and invasion and 
slightly reduced integrin expression. The simultaneous exposure of cells to  -
MSH and TNF-  clearly attenuated the response of cells to TNF-  with 
respect to invasion and expression of  3 and  4 integrin subunits. 
 
 TNF-   (300 
U/ml) 
-MSH (10
-7 
M) 
TNF-  (300 
U/ml) and  -
MSH (10
-7 M) 
Attachment  +10%  -23%  To be done 
Invasion +45%  -47%  -16% 
Integrin 
expression 
    
3 +28%  -15%  -18% 
4 +90%  -15%  -20% 
1 +65%  -22%  +25% 
 
Conclusions: The ability of TNF-  to increase integrin subunit expression, 
cell attachment and cell invasion is consistent with an inflammatory 
environment promoting melanoma invasion; the ability of  -MSH to 
attenuate the response to TNF-  is also consistent with     -MSH acting in an 
anti-inflammatory capacity to oppose metastatic spread. 
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INTERLEUKIN-12 POLYMORPHISMS MAY INFLUENCE  THE 
HOST MUCOSAL RESPONSE TO HELICOBACTER PYLORI. 
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AIM: Cytokine function is believed to play a role in benign and malignant 
mucosal disease. Cytokine polymorphisms at host genetic level may be 
important in determining susceptibility to different mucosal responses. The 
aim of this study was to examine the polymorphisms of interleukin-12 (IL-
12), a pro-inflammatory cytokine, in a large benign dyspeptic group with a 
high prevalence of H. pylori infection. 
METHODS: The study cohort, a dyspeptic population (n=300) on acid 
suppression therapy, was subdivided into ulcer (n=96), non-ulcer (156) and 
“not investigated” (n=48) categories. DNA was extracted from peripheral 
blood leucocytes and the distribution of the IL-12 alleles was determined by 
polymerised chain reaction, followed by restriction enzyme digestion. 
RESULTS: The genotype frequencies for the study population were A/A 
66.3%, A/C 29.7% and C/C 4%, which are very similar to our normal control 
frequencies of 64.2%, 31.6% and 4.2% respectively. However, the genotype 
frequencies for the ulcer (42 patients) versus non-ulcer (56 patients) in the 
helicobacter positive group were 59.5%, 38.1%, 2.4% and 78.6%, 16.1%, 
5.4% respectively (p=0.042). 
CONCLUSIONS: There is a significant difference between the helicobacter 
positive ulcer and non-ulcer patients. We previously demonstrated a similar 
increased frequency of the A/A genotype in H. pylori positive gastro-
oesophageal cancer patients. This study therefore suggests that the 
polymorphisms of the pro-inflammatory cytokine IL-12 may influence the 
host mucosal response to H. pylori infection. 
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CHARACTERISATION OF THE GENE ENCODING EMAP-II, A 
TUMOUR-DERIVED PRO-INFLAMMATORY CYTOKINE  
YM Heng*, P Symonds and JC Murray. Cancer Research UK Dept of 
Clinical Oncology, University of Nottingham  
 
The 20kDa pro-inflammatory cytokine EMAP-II, secreted by tumour cells 
under stress, is synthesized as a precursor of 34kDa (proEMAP-II) and was 
originally believed to be encoded by a 1.1kbp cDNA. However, the origin of 
EMAP-II remains unclear. Recently, a 1.25kbp cDNA reported to encode 
p43, a 43kDa component of the hamster multisynthase complex, was found to 
have high homology with the proEMAP-II cDNA, but contained additional 5’ 
sequence. We have used a variety of genomic and RNA-based techniques to 
help elucidate the relationship between EMAP-II and p43 proteins. By 
database searches we have identified a genomic contig of ~117kbp containing 
the functional EMAP-II gene. This gene is approximately 30kbp in size, 
comprises 7 exons, and possibly shares a bi-directional promoter with a novel 
gene, arranged in head-to-head fashion. By RT-PCR, we cloned additional 5’ 
cDNA sequences from human cells, corresponding to the first 170bp of 
sequence of the hamster p43 cDNA. The two species demonstrate sequence 
divergence in the 5’ region of the cDNA. The hamster sequence contains 
translation start sites appropriate for the predicted p43 protein as well as 
34kDa EMAP-II proteins, while the human sequence contains a start site for 
a 34kDa protein but not p43. This is in agreement with western blotting with 
polyclonal antibodies against EMAP-II, which revealed the presence of 
~43kDa and 34kDa bands in extracts of hamster cells. Human cell extracts 
however, do not express a 43kDa band, but only a 34kDa band. Thus it 
appears that humans do not express a homologue of the hamster p43 protein. 
The reasons for this evolutionary divergence are currently unclear. We have 
also explored the expression of EMAP-II mRNA by northern analysis to 
determine the size and distribution of the mRNA in human tissues. EMAP-II 
mRNA was most abundant in the adult testis. Furthermore, the same EMAP-
II probe identified 3 RNA transcripts of sizes ~1.3kb, 2.0kb and 2.6kb. A blot 
of mRNA extracted from several tumour cell lines also showed expression of 
the same 3 transcripts as in normal tissues. The significance of multiple 
hybridising transcripts is unknown, but these could represent alternatively or 
incompletely spliced transcripts. We are currently investigating this and the 
activity of the promoter region by reporter assays. 
This work is supported by Cancer Research UK 
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TUMOUR-DERIVED EMAP-II INHIBITS PROLIFERATION AND 
INDUCES APOPTOSIS IN LYMPHOCYTES  
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1, RA Robbins
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Murray. Cancer Research UK Dept of Clinical Oncology, City Hospital, and 
1Division of Immunology, Queens Medical Centre, University of Nottingham 
 
EMAP-II (endothelial monocyte-activating polypeptide II) was first detected 
in supernatants of murine fibrosarcoma cells. In vitro, EMAP-II induces 
procoagulant activity on the surface of endothelial cells, increased expression 
of E-and P-selectins and TNF Receptor-1, and is chemotactic for monocytes 
and neutrophils. More recent data suggest that EMAP-II induces apoptosis in 
a number of cell types. Therefore EMAP-II may play a role in tissue 
remodeling, by inducing cell death in selected populations, simultaneously 
encouraging the activity of phagocytic cells to clear cellular debris. In spite of 
this accumulating in vitro data, the role of EMAP-II in tumours is not 
understood. We have hypothesized that EMAP-II may regulate activity of 
immune effector cells within neoplastic tissues, and have investigated its 
effects on lymphocytes. In a first set of experiments, we treated peripheral 
blood mononuclear cell preparations (PBMC) with recombinant EMAP-II, 
prior to stimulation with PHA to induce lymphocyte proliferation. EMAP-II 
caused a dose-dependent inhibition of 
3H-thymidine incorporation (70% 
suppression at 200nM). Consistent with this, use of the CFSE dye dilution 
technique demonstrated a significant reduction in the number of cell divisions 
following EMAP-II treatment. Apoptosis was assessed in the same 
experiments by flow cytometry using the Annexin-V/propidium iodide 
technique. Treatment with EMAP-II induced apoptosis in lymphocytes 
stimulated by mitogen PHA, but not in un-stimulated cells. In the second 
series of experiments, DLD-1 colorectal adenocarcinoma cells, which express 
EMAP-II, were co-cultured with Jurkat (T-cell leukaemia) cells, to determine 
whether EMAP-II produced by the colorectal tumour cells can induce cell 
death in Jurkat cells. DLD-1 colorectal cancer cells express the 34kDa form 
of EMAP-II; and we showed by ELISA that these cells secrete EMAP-II into 
the culture medium in response to the combination of TNF-alpha and 
Interferon-gamma (TNF/IFN). By Annexin-V/PI labeling, treatment of Jurkat 
cells with recombinant EMAP-II alone induced significant apoptosis. Co-
culture of Jurkat cells with untreated DLD-1 cells induced some apoptosis of 
Jurkat cells; however a significant increase in killing of Jurkat cells was 
observed following pre-treatment of DLD-1 cells with TNF/IFN. Similar 
results were obtained when Jurkat cells were incubated with conditioned 
medium from TNF/IFN-treated DLD-1 cells. These effects could be partially 
reversed by addition of polyclonal antibodies against EMAP-II to the co-
culture. Our data suggest that EMAP-II released by tumour cells may be 
cytotoxic to lymphocytes through an unknown mechanism, and may 
constitute a component of a novel immunosuppressive pathway in solid 
tumours. 
This work is supported by Cancer Research UK 
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VEGF IS A POTENT ANGIOGENIC FACTOR IN TUMOURS OF 
THE EWING’S SARCOMA FAMILY  
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Angiogenesis plays an important role in tumour growth, invasion and 
metastasis. Recently we have demonstrated that enhanced neovascularisation 
is a marker of poor prognosis for over-all and event-free survival in patients 
with tumours of the Ewing’s Sarcoma Family (ESFTs). This suggests that the 
process of angiogenesis plays an important role in these tumours. The aims of 
this study were to investigate the expression and production of the angiogenic 
growth factors vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF) and platelet derived growth factor (PDGF) in ESFT 
cells. Potential autocrine and/or paracrine effects of these growth factors were 
also investigated. The effects of anti-tyrosine kinase receptor compounds 
targeting VEGF (SU5416) or VEGF, bFGF and PDGF (SU6668) receptors 
on ESFT growth in vitro and in vivo were evaluated.  
Production and secretion of VEGF, bFGF, PDGF-AB and PDGF-BB by 6 
ESFT cell-lines was examined by reverse transcriptase polymerase chain 
reaction (RT-PCR) and ELISA (R+D Systems). Expression of VEGF and its 
receptors Flt-1 and Flk-1 (KDR) was investigated by RT-PCR and Western 
blotting (WB). Potential autocrine and/or paracrine effects of VEGF were 
investigated using an antihuman VEGF neutralising antibody (R+D Systems) 
and the anti-tyrosine kinase receptor molecules (SUGEN). The effects of the 
anti-tyrosine kinase receptor compounds SU6668 and SU5416 (SUGEN) 
were also investigated in vivo following ESFT implantation in NuNu mice.  
All 6 ESFT cell lines studied produced and secreted VEGF into the media, as 
demonstrated by RT-PCR of cell extracts and ELISA on cell-conditioned 
media. In contrast bFGF, PDGF-AB and PDGF-BB were not detected in 
conditioned media. Different isoforms of VEGF were identified by WB; 
these were confirmed by RT-PCR to be VEGF121 and 165.   ESFT cells 
differentially expressed Flt-1 and Flk-1 (KDR), although using neutralising 
antibodies to VEGF or anti-tyrosine kinase receptor compounds no evidence 
of an autocrine and/or paracrine role for VEGF was found. Treatment of 
NuNu mice ip with SU5416 (25mg/kg/day) or SU6668 (100mg/kg/day) 
significantly reduced ESFT xenograft growth (p<0.05, p<0.001 respectively). 
Furthermore SU6668 (100mg/kg/day) caused a regression of established 
ESFT xenografts.  
In conclusion, VEGF appears to be an important angiogenic growth factor in 
ESFT. Targeting VEGF and/or VEGF receptors may be of therapeutic benefit 
in patients with ESFT. 
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MVD PREDICTS DISEASE-FREE AND OVERALL SURVIVAL IN 
TUMOURS OF THE EWING'S SARCOMA FAMILY (ESFT) 
Andrea Simpson
1*, Robert Grimer
2, Charles Mangham
3, Catherine 
Cullinane
4, Ian Lewis
5, Susan A Burchill
1.  
1Candlelighter's Children’s 
Cancer Research Laboratory, Cancer Research UK Clinical Centre, 
4Department of Pathology and 
5Paediatric Oncology, St James’s University 
Hospital, Leeds, LS9 7TF, 
2Royal Orthopaedic Hospital, Birmingham B31 
2AP, 
3Department of Musculoskeletal Pathology, Birmingham B29 6AY, 
UK. 
 
There is a need for new prognostic markers and therapeutic targets in ESFTs. 
Since angiogenesis plays an important role in the growth, invasion and 
metastasis of many solid tumours, we have evaluated the prognostic 
importance of angiogenesis in ESFTs.  
Micro-vessel density (MVD), an established marker of angiogenesis, was 
assessed in cryostat sections of 29 primary ESFTs by immunohistochemistry 
for the endothelial cell marker CD31 (Pecam-1; Dako). Bound antibody was 
detected using a biotin-conjugated rabbit anti-mouse IgG (Dako) and an 
avidin-biotin-peroxidase complex (Dako). The brown precipitate was 
developed using 3’,3’ diaminobenzidine (DAB) substrate and sections 
counterstained with haematoxylin. Each section was scanned on a Zeiss 
Axioplan microscope at 160x magnification to identify three areas with 
greatest micro-vessel density, the vessel count was performed at 250x 
magnification for an overall area of 0.79mm
2 for each ‘hotspot’ identified. 
The mean micro-vessel count was calculated for each section and MVD 
expressed as the number of micro-vessels per mm
2. The tumours were 
classified into two groups, negative/low MVD (MVD<100) and high MVD 
(MVD>100). The time to first event and current disease status for each 
patient was obtained, and Kaplan-Meier survival curves plotted. Statistical 
differences between the curves were compared using the Log-Rank test. 
Tumour samples and clinical outcome information were only obtained when 
informed consent had been given.   
Twenty percent (7/29) of ESFTs had high MVD, consistent with their 
haematogenous ESFT macroscopy. Mean time to first event in patients with 
these tumours was 17 months, and overall survival 28 months. In contrast in 
the remaining 76% (22/29) time to first event was 32 months and over all 
survival was 48 months. High MVD was a statistically significant marker of 
both poor overall (P=0.04) and event free (P= 0.01) survival in this small 
cohort of patients. 
In conclusion, MVD is a marker of poor prognosis in patients with ESFT and 
might therefore be used to stratify patients with ESFT for therapy. Since 
MVD is prognostically significant for disease-free and overall survival this 
suggests that angiogenesis may play an important role in ESFT progression 
and metastasis. This implies that the process of blood vessel formation may 
be a potential target for therapeutic intervention in patients with ESFT.   
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EFFECTS OF SIGNALLING INHIBITORS ON ENDOTHELIAL 
CELL FUNCTIONS REQUIRED FOR NEOANGIOGENESIS. 
S. Brader*, W. Court, G. Box, S.A. Eccles, P. Workman, Cancer Research 
UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, 
Surrey, SM2 5NG, UK. 
 
Neoangiogenesis is critical to tumour growth and metastasis, and hence is an 
important generic target for therapeutic intervention in cancer. Angiogenesis 
is driven by a variety of cytokines; the most important of which are the 
vascular endothelial growth factor (VEGF) family. Several agents are in 
clinical development which attempt to prevent neoangiogenesis via inhibition 
of VEGF receptor activation (e.g. SU5416) or binding of endothelial 
integrins to extracellular matrix (eg Vitaxin) and tubulin assembly (e.g 
Combretastatin A4). Signalling pathways in endothelial cells are generally 
poorly understood, but we aim to explore selected targets for which there is 
some evidence for a role in tumour angiogenesis. The studies reported here 
have explored inhibitors of phosphoinositide 3 kinase (PI3K) and 
phospholipase C (PLC) in relation to endothelial cell  (EC) functions required 
for neoangiogenesis, viz proliferation, chemotaxis, matrix proteolysis and 
tubule differentiation. 
A relationship has been shown between PI3K activity and 
survival/proliferation and migration in several types of cells. We found that 
the PI3K inhibitor, LY294002, decreased human EC proliferation (IC50 = 
3M) and migration though a 3M Transwell filter (IC50 = 1.5M). It also 
reduced production of matrix metalloproteinase 2 (MMP-2) (IC50 =3M) in 
response to VEGF, as shown by gelatin zymography and confirmed by 
ELISA.  
PLC	 has also been shown to be important in tumour cell motility and 
invasion. U73122, a PLC inhibitor, inhibited endothelial cell proliferation at 
6.5M, migration (IC50 = 0.1M) and MMP-2 production (IC50 = 3M). 
Also, in contrast to LY294002, U73122 decreased EC differentiation in the 
matrigel tube formation assay, totally abolishing tube formation at 3M. The 
inactive analogue U73343, had no significant effects on EC functions. 
Interestingly, we found that EC grown on “physiological” substrates such as 
collagen 1 matrix were less sensitive to PI3K and PLC inhibitors, suggesting 
care in interpretation of effects seen in standard 2D plastic culture systems. 
These results identify PI3K and PLC as important molecules in endothelial 
cell responses to VEGF.  Current inhibitors are of relatively low specificity, 
and are not ideal for use in vivo. Future generations of PI3K and PLC 
inhibitors may have a useful role in cancer therapy by inhibition of several 
steps in the angiogenic cascade. 
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Tumour hypoxia is an adverse prognostic indicator for local control by 
radiotherapy, malignant progression and metastatic potential.  The incidence 
of metastases has not only been linked to hypoxia itself but to the expression 
of the transcription factor HIF-1 (Hypoxia Inducible Factor-1).  In order to 
uncouple the contribution of abnormal physiology (hypoxia) and de-regulated 
expression of HIF-1 in tumour growth metastases growth and response to 
therapy, we have used a panel of syngeneic and experimental tumours 
growing in mice.  The panel includes Hepa-1 wt and C4 cells which are 
proficient and deficient in HIF-1 function respectively. Both cell types form 
tumours in nude mice and equal sizes have similar levels of hypoxia.   
However, the C4 tumours are formed more slowly and are much more 
responsive to ionising radiation than are wt tumours. This is due to hypoxic 
cells not contributing to tumour radiation resistance.  Interestingly, 
administration of Hepa-1 wt and C4 cells to mice via tail vein injection 
results in a similar efficiency of lung colony  (artificial metastasis) formation. 
A second pair of cell types are the rat glioblastoma lines CNS-1 and 9L.  
CNS-1 cells have a robust HIF-1 response, (16 fold induction of HRE-driven 
marker gene expression under hypoxic conditions) whereas the 9L cells show 
no hypoxia mediated gene induction but rather constitutive over expression 
of HIF-1 function in air (170 fold).  It is of note, the 9L cells when grown as 
tumours in vivo respond to radiation in a similar manner to the Hepa-1 C4 
cells (ie. hypoxic cells not contributing to radiation resistance). 
The last group of tumours include B16 f10 cells syngeneic in C57 mice and 
KHT cells syngeneic in C3H mice.  The B16 cells were chosen in this study 
because they have the greatest HIF-1 response (300 fold due to little, if any, 
aerobic HIF expression).  The KHT cells were used because they have an 
extremely reproducible temporal and special distribution of metastasis from a 
primary subcutaneous tumour. Taken together, this panel of tumours will 
allow us to dissect out the importance of hypoxia, hypoxia mediated gene 
expression and HIF-1 function in tumour growth, metastatic potential and 
response to therapy. 
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STUDYING THE ROLE OF iNOS IN TUMORIGENESIS UTILIZING 
THE ECDYSONE  SYSTEM 
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Studies have shown that nitric oxide generated by the enzyme nitric oxide 
synthase (iNOS) can have pro-tumor effects when produced in low levels and 
anti-tumor effects when produced in high levels. (Edwin C. Chinje and Ian J. 
Stratford –1997-Essays in Biochemistry 32: 61) Since stable clones that 
constitutively express very high levels of NO are often difficult to grow 
because of NO-induced toxicity, we have chosen an inducible approach. The 
ecdysone system was used particularly because of its low basal level and high 
fold induction. After transfecting the cells with the receptor vector 
(pVgRXR) and the response vector (pIND SP1) (which has a multiple 
cloning site to insert the gene of interest lacZ or iNOS), gene expression is 
induced by the addition of the steroid ecdysone or its analogue ponasterone 
A, (Pon A). (Enrique Saez, et al. –1997- Current Opinion in Biotechnology 8: 
608) (Enrique Saez, et al. –2000- PNAS 97: (26) 14512). Since there is no 
data about the level at which the effect of NO turns from pro- to anti- 
tumorigenic, the aim of this study is to tightly regulate iNOS gene expression 
and consequently NO production so that the level can be resolved. This will 
then allow the interpretation of the dual role of NO on apoptosis and 
angiogenesis. 
The ecdysone system was initially evaluated using the lacZ reporter gene. A 
stable clone of HT-1080 (human fibrosarcoma) expressing the ecdysone 
responsive cassette was generated. In vitro, the lacZ gene expression and 
activity as a function of Pon A concentration (0 to 20M for 24 hours of Pon 
A exposure) was observed. Results showed increasing activity of the -
galactosidase enzyme with maximum induction of 17 fold at 20M. The 
stable clone was then grown in vivo to a size of 250-300 mm
3 and Pon A 
administered by intraperitoneal injection (0, 1, 2 mg/mouse). After 24hrs
 the 
tumors were excised. They were either fixed or treated with X-gal staining or 
homogenized and -galactosidase activity measured. The results showed 
increasing activity as the concentration of Ponasterone A increased.  
Having tested the ecdysone system using the lacZ reporter gene, the system 
was used to tightly regulate iNOS levels. A stable clone of HT-1080 
containing the iNOS gene inserted in the ecdysone cassette was generated. 
The clone was exposed to a range of Pon A concentrations (0 to 20 M) and 
assayed to measure iNOS activity. The nitrite/nitrate content measured in the 
plasma reflected an increase in iNOS expression as Ponasterone A 
concentration increased. An immunocytochemistry approach was also used to 
measure iNOS induction. After staining the cells with iNOS specific 
antibodies, it was found that the percentage of immunoreactive cells 
increased with increasing Pon A concentration reaching a maximum of 21% 
with 30M Pon A. The NOS L-Citrulline assay showed that the clone 
exhibited maximal iNOS activity levels (21.5mg/ml/min) when exposed to 
20M Pon A as compared with no activity with the wild type HT-1080. 
These results provide us with a unique opportunity to study the dual role of 
NO on apoptosis, tumor growth, and vascularization.  
 
 
 
 
 
 
 
 
Poster Presentations
S96
British Journal of Cancer (2002) 86(Suppl 1), S34–S121 ã 2002 Cancer Research UKP206 
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Hypoxic regions in tumours develop because tumour cell growth is faster 
than the growth of the endothelial cells that compose the blood vessels and 
also because the newly formed vascular supply is disorganised. In order for 
tumour cells to survive and proliferate under these conditions they initiate the 
transcription of a number of genes. These include glycolytic enymes e.g. 
phosphoglycerate kinase (PGK), angiogenic factors e.g. vascular endothelial 
growth factor, regulators of blood flow e.g. nitric oxide synthase and 
regulators of red blood cell production e.g. erythropoietin. We have 
previously demonstrated that cell lines that lack subunits of the best-
characterised transcription factor responsible for hypoxic induction of genes 
(HIF-1) are less tumourigenic than wildtype cells. In addition, HIF-1 over 
expression is common in malignant disease and has recently been identified 
as an adverse prognostic indicator in a variety of cancers. Hence, this 
transcription factor could be a valid therapeutic target. There are two main 
transcription factors that facilitate hypoxic control of gene expression, 
hypoxia inducible factor 1 (HIF-1) and hypoxia inducible factor 2 (HIF-2). 
They are heterodimers. Both transcription factors share the same  subunit 
that is stable in normoxic conditions. The  subunits share 48% sequence 
identity and are subject to oxygen dependent degradation. In this study we 
have investigated the consequences of producing dominant negative forms of 
the   subunits by removing domains essential to their function but that 
should still allow heterodimers to form with the  subunit. The functionality 
of the dominant negatives has been tested in vitro using transient co 
transfection of a vector containing a hypoxic response element (HRE) driven 
luciferase reporter and a vector expressing the dominant negative  subunit. 
The dominant negative  subunits reduced PGK, lactate dehydrogenase A 
(LDH-A) and carbonic anhydrase 9 (CA-9) HRE driven luciferase reporter 
gene expression in breast carcinoma, glioma, fibrosarcoma and lung 
carcinoma cell lines under hypoxic conditions. Along side the dominant 
negative study a small molecular inhibitor is also being validated using the 
same reporter techniques and has shown robust inhibition of HRE-mediated 
transcription. Stable cell lines are now being generated that over express the 
dominant negative proteins. This will allow the effect of inhibition of 
hypoxia induced gene expression on cell growth in vitro and in vivo to be 
investigated.  In addition these constructs are being incorporated into an 
adenoviral system to evaluate the potential therapeutic effects of this 
dominant negative approach on established tumour xenografts.  
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Aims 
Malignant mesothelioma (MM) is a fatal tumour of the pleura, associated 
with asbestos exposure, which is expected to double in incidence by 2020.  
MM is resistant to current therapy and has a median prognosis of 
approximately 6 months.  Angiogenesis, as assessed by microvessel counts 
(MVCs) is an established prognostic factor in MM.  Microscopic tumour 
necrosis (TN) has not been described or characterised in MM, although 
necrosis is a poor prognostic factor in other solid tumours.  The aim of this 
study was to evaluate the incidence, correlations and significance of TN in 
MM. 
Methods 
Clinicopathological prognostic factors and European Organisation for 
Research and Treatment of Cancer (EORTC) and Cancer and Leukemia 
Group B (CALGB) prognostic scores were derived from case-note review of 
a cohort of 171 MM patients presenting between 1987 and 2001.  MVCs 
were obtained from CD34-immunostained tumour sections.  TN was assessed 
in routine formalin-fixed, paraffin-embedded, Haemotoxylin and Eosin 
stained tumour sections by two independent observers (blind to outcome) 
with a scale 0 (no necrosis) to 3 (frequent/large areas of necrosis).  TN was 
correlated with survival by Kaplan-Meier and Log Rank analysis.  A 
stepwise, multivariate Cox model was used to evaluate the impact on survival 
of TN, MVCs, known prognostic factors and the prognostic scoring systems 
proposed by the EORTC and CALGB.  Patients surviving less than 30 days 
were excluded to avoid bias from peri-operative deaths. 
Results 
171 patients were assessed, of whom 17 (10%) died within 30 days.  Overall 
median survival was 186 days.  TN was identified in 39 cases (23%).  TN 
was correlated with a high preoperative platelet count (p=0.04), and low 
haemoglobin (p=0.01) and high MVC (p=004).  The presence of TN was 
associated with poor survival in univariate Cox proportional hazards analysis 
(HR 1.74, 95%CIs 1.15 – 2.63, p=0.009).  Median survival in patients with 
and without TN was 158 and 248 days respectively.  TN contributed to both 
CALGB (p=0.02) and EORTC (p=0.02) but not to MVCs (p=0.71) in 
multivariate Cox models. 
Conclusions 
TN necrosis correlates with angiogenesis in MM.  Assessment of TN is a 
quick and reproducible technique, providing prognostic data in MM which is 
independent of the CALGB and EORTC prognostic scoring systems. 
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ENDOSTATIN IN CIRCULATING BLOOD CELLS 
Nash GF*, Chopada A, Kakkar AK,   Imperial College, London 
 
INTRODUCTION  
Endostatin is an endogenous angiogenesis inhibitor demonstrated to reduce 
tumour growth in vivo, however it has few in vitro effects and little is known 
about either its source or mechanism of action. Vascular endothelial growth 
factor (VEGF), an important angiogenic stimulant opposing the effects of 
endostatin, is released by platelets and neutrophils. We aimed to investigate 
whether platelets or neutrophils also store endostatin. 
METHODS  
We measured the effect on platelets of endostatin addition, using a standard 
platelet aggregometer. In addition, endostatin release was measured by 
standard ELISA using pooled platelets obtained from the national blood 
bank. Washed platelets were compared to platelet-rich plasma (PRP), both at 
1x10
8/ml concentration. After ethical consent, blood was collected from 21 
controls and 21 units of bank blood and after centrifugation at 3000 rpm the 
supernatants underwent endostatin ELISA. 
RESULTS  
Recombinant endostatin added to washed platelets demonstrated impressive 
inhibition of thrombin-induced aggregation, though this effect was wholly 
attributable to the endostatin buffer. There was a threefold increase in 
endostatin on stimulating pooled PRP (20.6 ng/ml vs. 60.4 ng/ml, P<0.001) 
with one unit of thrombin. Washed platelets released 1.5ng/ml (+/- 0.4) 
endostatin compared to washed platelet lysate 4.4 ng/ml (+/- 1.6, P<0.001).  
Clinically endostatin levels were not associated with platelet counts, but were 
positively correlated with neutrophil counts (R= 0.42, P=0.05), this was 
further supported by the finding that the total endostatin levels in the buffy 
coat (white cells) of donor blood was 20.0 ng/ml  (+/- 0.88). 
CONCLUSIONS  
These data suggest that rather than endostatin inhibiting platelets, human 
platelets release endostatin upon thrombin stimulation. This together with the 
finding that endostatin levels correlate with neutrophil count strongly suggest 
that the manipulation of platelet and neutrophil activation may have 
important effects upon the endostatin levels of cancer patients. 
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CYCLOOYGENASE INHIBITORS MODULATE ENDOTHELIAL 
CELL APOPTOSIS, PROLIFERATION AND ANGIOGENESIS 
 SH Teh*, ADK Hill, A Lee, L Young, E McDermott, N O’Higgins. Depart. 
of Surgery, St Vincent’s University Hospital, Ireland. Depart. of Surgery
, 
Mayo Clinic, USA 
 
Aims: - Several mitogens, including basic fibroblast growth factor (bFGF), 
are secreted during tumour growth. This pro-angiogenic environment 
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of bFGF and COX inhibitors on endothelial cells apoptosis, proliferation and 
tubal formation. Methods and Results: -bFGF exerts potent cytoprotective 
(by intracellular nucleosomes assay and TUNEL) and pro-proliferative effect 
(by BrdU incorporation assay) on human umbilical vein endothelial cells. 
Non-selective COX inhibitor (aspirin) and selective COX II inhibitor 
(meloxicam) but not selective COX I inhibitor (SC 560) are pro-apoptotic 
and anti-proliferative in quiescent and bFGF stimulated endothelial cells. 
bFGF increased expression of prostaglandin E2, a COX II cleaved arachidonic 
acid product. Both bFGF and PGE2 induced a significant increase in tubal 
formation. Aspirin and meloxicam prevented neovascularization of 
endothelial cells even in the presence of bFGF. Conclusion: - Overall our 
data demonstrate that bFGF and PGE2 are potent pro-angiogenic factors. 
COX inhibitors can negatively modulate the angiogenic effect of bFGF. It 
also inhibits the activities of COX enzyme and decreases production of PGE2 
which subsequently leads to inhibition of the process of angiogenesis. 
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THE MECHANISM OF ACTION OF ENDOSTATIN ON QUIESCENT 
AND STIMULATED ENDOTHELIAL CELLS  
SH Teh*, ADK Hill, A Lee, McDermott E, O’Higgins N.  
Depart. of Surgery, St Vincent’s University Hospital, Ireland.  Depart. of 
Surgery 
, Mayo Clinic, USA 
 
Aims:- Endostatin is a potent endogenous peptide that has a negative 
regulatory effect on endothelial cells (EC) but the mechanism remains 
unclear. This study was designed to assess the apoptotic and anti-proliferative 
effect of endostatin in stimulated and quiescent endothelial cells. 
METHODS:-Human umbilical vein endothelial cells (EC), were treated 
VEGF, and bFGF, and endostatin with and without VEGF and bFGF. After 
24 hours incubation, apoptosis was measured by detecting intracellular 
nucleosomes and proliferation was quantified by the bromodeoxyuridine 
incorporation assay. RESULTS:-Endostatin alone increased apoptosis by 42 
% and in the presence of VEGF and bFGF the apoptosis was reduced to 3 % 
and 15 % respectively (p=0.02). In EC treated with VEGF and bFGF, 
apoptosis was reduced by 25 % and 27 % respectively (p=0.03). Endostatin 
decreased the proliferative effect of VEGF, (36 % to 22 %) and bFGF (23 % 
to 8%). In unstimulated EC, endostatin alone had no effect on proliferation. 
CONCLUSION:-In quiescent EC, the anti-angiogenic effect of endostatin is 
mediated by inducing apoptosis.  However in stimulated EC, endostatin has 
an anti-proliferative effect. 
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BLOCKADE OF VASCULAR ENDOTHELIAL GROWTH FACTOR 
RECEPTORS INCREASES TUMOUR CELL APOPTOSIS 
Martin P. Barr
*, David J. Bouchier-Hayes, Judith H. Harmey. 
Department of Surgery, Royal College of Surgeons in Ireland,  Education & 
Research Centre, Beaumont Hospital, Dublin 9, Ireland. 
 
Angiogenesis is critical for tumour growth and metastasis. Several 
angiogenic factors have been identified, including the particularly potent 
cytokine, VEGF (vascular endothelial growth factor). We have previously 
shown that VEGF acts as a survival factor for murine and human mammary 
adenocarcinoma cells by upregulating Bcl-2, thereby inhibiting apoptosis 
1,2. 
Antibodies raised against VEGF have been shown to suppress tumour growth 
in vivo
3, indicating that VEGF antagonists may have therapeutic applications 
as inhibitors of tumour-induced angiogenesis. To date, a number of VEGF 
receptors have been identified, namely Flt-1, Flk-1/KDR and more recently 
Neuropilin-1. In this study, we aimed to identify peptides blocking the 
binding of VEGF to its specific receptors on breast tumour cells. 
Total RNA was isolated from murine (4T1) and human (MDA-MB-231) 
mammary adenocarcinoma cells and cDNA synthesised by reverse 
transcriptase for PCR using primers specific for the VEGF receptors Flt-1 
and Flk-1/KDR. Human umbilical vein endothelial cells were used as a 
positive control. Neuropilin-1 expression was analysed by Western blot. 
Peptides were designed to block KDR and Neuropilin-1 receptors. Cells 
(1x10
4) were seeded in 96-well plates and treated with a repertoire of 
peptides for 24hr in the presence/absence of recombinant VEGF (10ng/ml). 
Tumour cell apoptosis was measured using the TUNEL assay (TdT-mediated 
dUTP nick end labelling). 
Flt-1 and KDR receptors were expressed on human MDA-MB-231 tumour 
cells and Flt-1 in murine 4T1 tumour cells. A 130kD protein corresponding to 
Neuropilin-1 was identified in both tumour cell lines. Peptides directed 
specifically against the VEGF receptors Flk-1/KDR and Neuropilin-1 
induced tumour cell apoptosis, an effect that was blocked by the addition of 
recombinant VEGF. 
Our results identify an additional role for VEGF in tumour growth. In VEGF 
receptor-expressing tumour cells, anti-KDR and anti-Neuropilin-1 peptides 
increase apoptosis by blocking VEGF binding to its cognate receptors. 
1 Pidgeon, GP., Barr, MP, Harmey, JH., Foley, DA., Bouchier-Hayes, DJ., 
2001. Brit. J. Cancer, 85, 273. 
2 Harmey, JH., Bouchier-Hayes, DJ., 2002. BioEssays (In Press). 
3 Kim, KJ., Li, B., Winer, J., Armanini, M., Gillet, N., Philips, HS., Ferrara, 
N., 1993. Nature, 362, 841. 
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COX-2 INHIBITORS REDUCE VEGF PRODUCTION IN 
NORMOXIA AND HYPOXIA. 
G Roche-Nagle*, J Harmey, D Bouchier-Hayes. Department of Surgery, 
Beaumont Hospital, Dublin 9. 
 
Tumour strategies must be effective in normoxic and hypoxic conditions. 
Vascular endothelial growth factor (VEGF) has been shown to be a survival 
factor for tumour cells and is up regulated by hypoxia. Cyclooxygenase-2 
(COX-2) inhibitors decrease experimental breast cancer growth through a 
VEGF mediated pathway. We examined the effect of COX-2 inhibition on 
tumour cell expression of VEGF in a normoxia and hypoxia environment. 
Murine (4T1) metastatic mammary carcinoma cells were treated with COX-1 
inhibitor (SC-560), COX-2 inhibitor (NS-398) or indomethacin under 
normoxic and hypoxic conditions. VEGF was assayed by ELISA and 
expressed as pg /µg cell protein. 
 
Treatments          Normoxia            Hypoxia  
Controls            1.40               2.58 
Concentrations     1µM          5µM            1µM            5µM            
Cox 1 inhibitor    1.35  1.28    1.87  1.53 
Cox 2 inhibitor    0.54*# 0.75*#    0.87*# 0.81*# 
Indomethacin    1.08  0.68*    1.24  0.79* 
 ANOVA; non parametric analysed with Kruskal Wallis; *=p<0.05 Mann-
Whitney Test; # =p<0.05 N=9 
 
In 4T1 cells, hypoxia increased VEGF production 2-fold relative to controls. 
Indomethacin or the selective COX-2 inhibitor (NS-398) reduced VEGF 
production under normoxic and hypoxic conditions. They were found to be 
more sensitive to COX-2 under hypoxic conditions. COX-1 inhibition (SC-
560) did not alter VEGF production. Thus COX-2 inhibition down regulates 
VEGF release from cancer cells under normoxic and hypoxic conditions, and 
as such satisfies an important requirement for an anti-cancer treatment. 
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PROTEOLYSIS OF HUMAN FIBULIN-1 IN BREAST CARCINOMAS 
AND IN VITRO 
Lisa M. Greene
a*, Waleed O. Twal
b, Enda Mc Dermott
c, Niall O’ Higgins
c, 
Michael J. Duffy
a, W. Scott Argraves
b, and William M. Gallagher
a,+ 
aConway Institute of Biomolecular and Biomedical Research, Department of 
Pharmacology, University College Dublin, Belfield, Dublin 4, Ireland. 
bDepartment of Cell Biology and Anatomy, Medical University of South 
Carolina, 173 Ashley Avenue, Charleston, South Carolina, USA. 
cConway 
Institute of Biomolecular and Biomedical Research, Department of Surgery, 
University College Dublin, Belfield, Dublin 4, Ireland. 
 
Fibulin-1 is a secreted glycoprotein and has been implicated in the regulation 
of tumour development. For example, fibulin-1 can suppress cell adhesion, 
motility and invasion of a variety of tumour cell lines in vitro, as well as 
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an essential component of extracellular matrix (ECM) structures and may be 
subjected to proteolysis during tumour development.  In this study, we 
examined the sensitivity of immunoaffinity-purified human fibulin-1 protein 
to proteolysis by MMP-3, –7 and other tissue proteases. Proteolysis of 
fibulin-1 was analysed by Western blotting using an N-terminal-specific 
monoclonal antibody. Fibulin-1 (100kDa) was readily cleaved by MMP-7 
and thrombin in a dose- and time-dependant manner. Cleavage of fibulin-1 
by thrombin produced a 50 kDa N-terminal fragment. A 30 kDa N-terminal 
fragment and a corresponding C-terminal 70 kDa fragment of fibulin-1 were 
detected following digestion with MMP-7. Digestion of fibulin-1 by plasmin 
and leucocyte elastase gave rise to a more extensive cleavage pattern 
resulting in fragments ranging from 70 - 30 kDa. Western blot analysis using 
the N-terminal-specific antibody was used to determine if proteolysis of 
fibulin-1 occurs in vivo in breast cancer. In addition to full-length fibulin-1, 
we identified several immunoreactive N-terminal fragments (55, 50, 30, and 
25 kDa) in human breast tissue. The 55 kDa proteolytic fragment of fibulin-1 
was detected in both normal and neoplastic breast tissue.  However, the 50 
kDa fragment of fibulin-1 was found more frequently in benign breast tumors 
(5/5, 100%) (Chi-square = 4.55, P = 0.03) and in breast carcinomas (35/39, 
90%) (Chi-square = 17.22, P 
 0.0001) than in normal breast tissue (6/18, 
33%). Occurrence of the 25 kDa fragment was limited to just 5% of the 
breast carcinomas analysed. Immunoreactive fragments of fibulin-1 were also 
detected in the cell extract of 6 breast cancer-derived cell lines. These 
differences in terms of fibulin-1 proteolysis between normal and neoplastic 
breast tissue presumably reflect deregulated proteinase activity in the 
carcinomas. We have shown for the first time that human fibulin-1, a 
candidate tumour suppressor gene, is readily cleaved by a number of 
proteases in vitro and is proteolytically modified during breast cancer 
development. [Supported by the Irish Cancer Society, Enterprise Ireland and 
the Association for International Cancer Research (WG) and NIH Grant 
HL52813 (WSA)].  
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EFFECT OF CELL CYCLE ON CELLULAR HIF-1 
LOCALISATION 
Gabi U. Dachs*, Chryso Kanthou, Olga Greco, Claudia Coralli and Gillian 
M. Tozer 
Gray Cancer Institute, Mount Vernon Hospital, Northwood, HA6 2JR 
 
The field of hypoxic gene regulation has expanded exponentially in recent 
years. An oxygen responsive enhancer sequence (hypoxia-responsive 
element, HRE) and its corresponding transcription factor (hypoxia inducible 
factor 1, HIF-1) have been identified (reviewed in Dachs and Tozer, 2000, 
Eur J Cancer 36, 1649). HIF-1 is a heterodimer consisting of the subunits 
HIF-1 and HIF-1, both belonging to the basic-helix-loop-helix per-aryl 
hydrocarbon receptor nuclear translocator-sim family of transcription factors. 
HIF-1 is common to all mammalian cells tested to date and has also been 
detected in all human tissue and organs assayed. Several recent studies 
demonstrated that the majority of clinical tumour specimens overexpressed 
the HIF-1 protein subunit. Controlling gene expression via the HIF-1/HRE 
system has therefore been proposed as a way of targeting gene therapy to 
solid tumours (Dachs et al., 1997, Nature Medicine 3, 515). 
The activation of HIF-1 is a multistep process of hypoxia-dependent nuclear 
import, de-repression of the activation domain and recruitment of the p300 
coactivator. The amount of HIF-1 protein increases during hypoxia and is 
degraded rapidly during reoxygenation in intact cells. HIF-1 and HIF-1 
bind in the cytosol and dimerisation is required for stable association with the 
nuclear compartment. We have analysed the cellular localisation of HIF-1 
by immunofluorescence in T24 bladder carcinoma, FaDu nasopharyngeal 
squamous carcinoma and MDA 231 breast carcinoma cells. A variation in 
staining and nuclear localisation was observed. Specifically, cells undergoing 
mitosis lost nuclear localisation following induction by the hypoxia mimetic 
agent, CoCl2. Distribution of HIF-1 throughout the cell cycle was analysed 
using FACS. The effect of overexpression of HIF-1, HIF-1, EPAS, p300 
and CBP on HIF-1 localisation following transient transfection of T24 cells 
were also analysed. 
Reporter gene analysis has shown that synthetic promoters containing HRE 
sequences derived from PGK1 (5x 18 bp) and VEGF (5x 18 bp) responded 
not only to hypoxic stimuli, but also to radiation (5 Gy) in transiently 
transfected T24 cells (Greco et al, submitted manuscript). The effect of 
ionising radiation on HIF-1 localisation was therefore determined. 
This work was funded by Cancer Research UK. 
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DYNAMIC CONTRAST ENHANCED MRI ASSESSMENT OF 
ACUTE MICROVASCULAR EFFECTS WITH CONVENTIONAL 
CYTOTOXIC CHEMOTHERAPY IN HUMAN TUMOURS. 
*KJ Lankester
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Background: Vascular targeting agents, such as combretastatin, cause acute 
reductions in tumour blood flow resulting in necrosis in animal models
1. 
Dynamic contrast enhanced MRI (DCE-MRI) kinetic parameters related to 
tissue permeability and perfusion can be used to quantify these effects (K
trans: 
volume transfer constant between blood plasma and the extravascular 
extracellular space (EES) and ve: volume of EES per unit volume of tissue). 
In a recent phase I trial, significant changes in K
trans and ve were seen 24 
hours after combretastatin using DCE-MRI
2. Combretastatin will be used in 
combination with cytotoxic agents in future trials. The latter are not thought 
to have specific acute effects on tumour vasculature. However, this has not 
been verified, and it will be important to distinguish the effects of 
combretastatin from any unexpected vascular contributions from the 
cytotoxic agent. Thus, the purpose of this study was to observe if cytotoxic 
agents have any acute effects on the tumour vasculature using DCE-MRI. 
Taxane and platinum based regimens were chosen as they are the likely 
choices for future trials. 
Methods: Three scans were done on consecutive days - 2 pre-treatment (for 
repeatability) and 1 post-treatment. Serial T1-weighted dynamic images were 
obtained before and after the bolus administration of IV Gd-DTPA (0.1 
mmol/kg). Chemotherapy was given after the 2
nd scan. The average time from 
the start of chemotherapy to the 3
rd scan was 21 hours. Repeatability statistics 
derived from the measurements on days 1 & 2 for the group were used to 
assess the effect of chemotherapy on day 3 for individual patients. The 
following statistics were used: the mean squared difference for the group 
(dSD); within patient standard deviation (wSD); within patient coefficient of 
variation (wCV); repeatability (r) 
3. 
Results: 9 women with gynaecological tumours have been imaged so far and 
7 were suitable for analysis. The average age was 56 years old and all had 
WHO performance status 2. The repeatability value for log10K
trans was –
33.6% to +50.7% and 11.8% for ve (wSD for log10K
trans = 0.0643 and for ve 
= 0.0427). So far, from the comparison of the day 3 measurement with the 
mean value of days 1 & 2, there has been no significant change in K
trans for 
any patient and no significant change in ve for 5/7 patients within 24 hours of 
the first cycle of conventional chemotherapy.  
Conclusion:  Results to date show no systematic changes in kinetic 
parameters related to perfusion/permeability. Further data are being acquired 
and we aim to recruit a total of 20 patients. 
References:  
1. Chaplin DJ et al. Br J Cancer 1999;80(S1):57 
2. Galbraith SM et al, Proc ASCO 2001:20:70a   
3. Bland JM & Altman DG. BMJ 1996;313:106 
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TUMOUR XENOGRAFT REGRESSION CAN BE INDUCED BY 
COMBINING THE VASCULAR-TARGETING AGENT ZD6126 
WITH THE VEGF RECEPTOR TYROSINE KINASE INHIBITOR 
ZD6474.   
A.J. Ryan*, J. Kendrew, D.J. Ogilvie, L.F. Hennequin, S.R. Brave, S.E. 
Ashton, J.A. Calvete, D.C. Blakey and S.R. Wedge. Cancer and Infection 
Research, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, 
United Kingdom. 
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exploiting differences between the endothelium of tumours and normal 
tissues to achieve a therapeutic anti-tumour effect. However, these 
approaches are mechanistically distinct: anti-angiogenics are intended to limit 
tumour growth and progression by preventing recruitment of new tumour 
blood vessels, while vascular-targeting agents aim to disrupt pre-existing 
tumour vasculature, leading to vessel occlusion and the induction of 
extensive tumor necrosis. Given their different mode of action, a combination 
of these two approaches may prove complementary. 
Since VEGF has a pivotal role in inducing pathological angiogenesis, 
inhibition of VEGF-signalling is viewed as a key anti-angiogenic strategy. 
We have developed the orally-active VEGF receptor tyrosine kinase inhibitor 
ZD6474 (Wedge S.R. et al., Proc. Amer. Assoc. Cancer Res., 42: Abst. 3126, 
2001) and shown it to elicit broad-spectrum anti-tumour activity in a range of 
models following chronic once-daily administration. The current study 
examined ZD6474 in combination with the novel vascular targeting agent 
ZD6126, which causes selective disruption of tumor vasculature (Blakey, 
D.C. et al., Proc, Amer. Assoc. Cancer Res., 42: Abst. 4421, 2001). ZD6474 
(50 mg/kg/day, p.o.) or vehicle was administered to mice bearing established 
Calu-6 human lung tumors (0.7 cm
3 volume) for two weeks, with or without 
a single dose of ZD6126 (100 mg/kg, i.p.) given on day 7. ZD6474 alone 
inhibited tumor growth significantly (73%, p = 0.001 by one-tailed t-test) 
while ZD6126 alone produced a transient growth delay (6% inhibition at the 
end of the experiment, p = 0.4). However, a combination of ZD6474 and 
ZD6126 inhibited growth of tumors completely (> 100%) with evidence of 
tumor regression post-ZD6126 administration. Similar experiments were 
performed in established Lovo human colorectal tumors (0.5 cm
3 volume) 
with daily administration of ZD6474 (50 mg/kg/day, p.o.) for 11 days and 
acute administration of ZD6126 (100 mg/kg, i.p., day 5). The combination 
again produced a greater effect than either agent alone, inhibiting tumor 
growth completely and inducing tumor regressions. These preclinical 
experiments do suggest that a combination of anti-angiogenic and vascular-
targeting agents may provide added therapeutic benefit.  
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CHARACTERISATION AND QUANTIFICATION OF AN 
ENDOTHELIAL CELL TUBE FORMATION ASSAY   
S.R. Brave*
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Angiogenesis, the formation of new blood vessels from pre-existing 
vasculature, plays a significant role in a number of pathological conditions, 
including tumour growth (Folkman & Shing, J. Biol. Chem, 267; 10931, 
1992). This complex multi-step process involves endothelial cell migration, 
proliferation and differentiation into tubules. We have examined an in vitro 
model of endothelial cell tube formation (AngioKit, TCS Biologicals, UK) 
with the aim of characterising levels of 3 angiogenic stimuli (VEGF, bFGF 
and IL-8) during the course of the assay. HUVECs and human fibroblasts 
were obtained as co-cultures (day 1; AngioKit). Cells were maintained at 
37
0C with 5% CO2 and the medium changed every 2-3 days. Aspirated media 
was stored for analysis of VEGF, b-FGF and IL-8 using ELISA.  
 
 
 
 
 
 
 
 
In the presence of exogenous b-FGF (~700pg/ml), high levels (> 1 ng/ml) of 
endogenous VEGF and IL-8 were apparent in the incubation media harvested 
on day 11. Under these conditions vessel growth in response to additional 
exogenous VEGF (20ng/ml) was low. In comparison, the removal of 
exogenous b-FGF from incubation media resulted in a 93% reduction in IL-8 
and a 35% reduction in VEGF (in media harvested at day 11). This enabled a 
greater response to exogenous VEGF to be demonstrated: conditions that 
were subsequently used to examine inhibitors of VEGF-receptor signalling.  
To quantify tubule growth a novel whole-well image analysis methodology 
was developed using a Zeiss KS400 3.0 image analyser (Imaging Associates 
Ltd).  Tubule formation was examined at day 11 following fixing and 
staining of tubules for CD31. The morphological parameters measured were 
total area of tubule growth, total tubule length, number of bifurcations, and 
total area of clusters (un-migrated cells). Small molecular weight inhibitors of 
VEGF-receptor tyrosine kinase activity have been investigated against each 
of these parameters. 
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Aim: Response to chemotherapy in solid tumours is conventionally assessed 
by dimensional measurements of CT scans after 3 months of treatment. 
Studies have shown that 18-F fluorodeoxyglucose positron emission 
tomography (FDG PET) on a dedicated PET (DPET) system may be able to 
predict response earlier than CT scans, however there are limitations with the 
current methods of quantitative analysis. Response assessment has not yet 
been examined with hybrid camera PET (HCPET). HCPET is more 
affordable and can be used for routine nuclear medicine imaging, but has 
lower resolution than DPET. HCPET has the advantage that it could be 
widely available in both cancer centres and cancer units.  
Method:  25 patients with metastatic disease having first or second line 
chemotherapy entered a study comparing FDG PET (HCPET) to CT scans 
and serum tumour markers for response assessment. FDG PET, CT scans and 
serum tumour markers were obtained pre-treatment and after 3 months of 
chemotherapy. An additional FDG PET scan was performed at 2-4 weeks 
after treatment to assess its predictive value. A novel method of semi-
quantitative analysis of the FDG PET scans has been developed to 
automatically define tumour volumes (segmentation) in an objective, 
reproducible and reliable manner. These segmented images are then analysed 
using count density histograms, which provide both a numerical and pictorial 
display of functional tumour changes with therapy. CT scans were measured 
according to the RECIST criteria.  
Results:  All patients who attained a partial response on CT at 3 months had 
a 15% or greater reduction in tumour FDG uptake at the 2-4 week time-point. 
No patients with progressive disease on CT at 3 months showed a 15% or 
greater reduction in tumour FDG uptake.  All patients with radiological stable 
disease who had a reduction in tumour FDG uptake at 2-4 weeks also had a 
fall in tumour markers. This may indicate a biological response to therapy 
that is not being detected by anatomical measures.  
Conclusion:  HCPET shows potential for predicting response to 
chemotherapy after only 2-4 weeks of treatment. The FDG PET scan results 
and the changes observed in serum tumour markers suggest that 
chemotherapy may be  producing a biological change which is not being 
detected by dimensional measurements alone.   
This study has approval from the Royal Free Hospital Local Research Ethics 
Committee (LREC) and the Administration of Radioactive Substances 
Advisory Committee (ARSAC). 
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DIFFERENTIAL EXPRESSION OF CA-IX IN HUMAN CARCINOMA 
CELL LINES 
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CA-IX is a member of the  class of carbonic anhydrases (CA) that catalyse 
the hydration of CO2 (H20 + CO2  H
+ + HCO3
-) and serve a wide range of 
physiological functions including acid-base regulation and respiration. CA-
IX is tumour-associated and may have potential roles in oncogenesis. CA-IX 
is upregulated by hypoxia, which is associated with increased aggressiveness, 
Day 1 Day 11 Day 1 Day 11
VEGF 85 ± 1.2 2000 ± 105 0 1300 ± 70
bFGF 400 ± 20 75 ± 18 0 0
IL8 100 ± 14 1375 ± 72 115 ± 55 95 ± 15
pg/ml  ± 
s.e.m
Basal medium + b-FGF Basal medium - b-FGF
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in maintaining the extracellular acidification common to solid tumours that is 
assumed to be related to enhanced proliferation, invasiveness and has 
implications for chemotherapeutic drug uptake and activity. The aims of the 
study were to assess the effect of anoxia for inducing CA-IX protein 
expression in a panel of cell lines, to identify if expression of CA-IX is 
related to cell growth and finally determine whether CA-IX expression can 
reflect itself in changes in drug uptake and toxicity.  
A panel of 16 cell lines was characterised for CA-IX protein expression 
under both aerobic and anoxic conditions by western blotting. The growth of 
MDA435 cells transfected with CA-9 and empty vector controls was assessed 
under aerobic and anoxic conditions by cell counting.  
The levels of CA-IX varied between cell lines from HT1080 and RT112 cells 
expressing very low levels to high expression in SW480 cells in aerobic 
conditions. A subset of the panel exhibited substantial anoxic induction of 
CA-IX (e.g. H647, HT29, MDA231, SW480). CA-IX expressing MDA435 
cells showed reduced growth compared to controls in air, however the 
inhibition was absent in anoxia.  
The majority of tumour cell lines tested expressed CA-IX to varying degrees 
but not all exhibited induction by anoxia, suggesting that the effect may be 
cell type specific.  Expression of CA-IX did not appear to provide a growth 
advantage to tumour cells under aerobic or anoxic conditions. Further studies 
will be carried out in which a selected panel of cells with high and low CA-
IX expression will be treated with a known CA inhibitor (acetazolamide) in 
combination with anticancer agents.  
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ALTERED SENSITIVITY TO HYPOXIA IN PROSTATE CANCER 
CELL LINES; HYPOXIA-INDUCED APOPTOSIS A 
MITOCHONDRIAL INDEPENDENT EVENT. 
Ronan N.T. Coffey*, R. William G. Watson, Cormac T. Taylor, John M. 
Fitzpatrick 
Department Surgery, Mater Misericordiae Hospital, Conway Institute, 
University College Dublin, Ireland. 
 
Hormone manipulation (androgen ablation) is the most effective treatment for 
advanced prostate cancer to date. This treatment however is palliative, as 
only a proportion of prostate cancers cells are dependent upon androgen for 
survival. Following androgen ablation, patients eventually relapse to an 
androgen independent state. At the molecular level, many factors have been 
implicated with the emergence of androgen independent prostate cancer. The 
ability of prostate cancer cells to survive in a hypoxic environment may be 
one of these contributing factors. The objectives of this study therefore were 
to assess the effects of hypoxia on apoptosis in an androgen sensitive LNCaP 
and insensitive PC-3 prostate cancer cell line; to identify a role for the 
caspases, a family of cell death proteases in this process. 
Cells were grown under hypoxia (1-5% 02 , 0- 72 hrs). Apoptosis was 
assessed by sub G0 propidium iodide incorporation and Annexin V staining. 
Hypoxic inducible factor-1 alpha (HIF-1) expression and mitochondrial 
cytochrome c release to the cytosol were assessed by Western blotting. 
Caspase activity was assessed using caspase 3, 6/8 and 9 AMC-tagged 
fluorescent substrates.  
The LNCaP cell line displayed no basal expression of HIF-1 under 
normoxia, but did undergo induced expression at 24-48 hrs hypoxia. The PC-
3 cell line on the other hand, constitutively expressed HIF-1 under both 
normoxia and hypoxia. Hypoxia resulted in cell death in the LNCaP cells 
with maximum percent apoptosis occurring at 72 hrs 1% hypoxia 
(28.4+2.1%) compared to normoxia (10.5+1.7%). PC-3 cells remained viable 
at 72 hr 1% hypoxia and displayed no increase in percent apoptosis 
(6.1+0.6% normoxia compared to 5.2+0/6% 72 hr 1% hypoxia). Apoptosis in 
the LNCaP cell line was associated with caspase 3 and 8 activation but was 
independent of caspase 9. This was confirmed by the inability to detect the 
release of cytochrome c from the mitochondria to the cytosol in the LNCaP 
cell line, a rate-determining step in the activation of caspase 9.  
We demonstrate that hypoxia elicits an apoptotic response only in the 
androgen sensitive LNCaP prostate cancer cell line, in what appears to be a 
mitochondrial and caspase 9 independent manner.  The ability of prostate 
cancer cells to grow in a hypoxic environment may a contributing factor 
leading to the development of the hormone refractory state. The constitutive 
expression of HIF-1 may represent an important survival factor in PC-3 
cells which are inherently more resistant to hypoxia-induced apoptosis than 
the androgen sensitive LNCaP cell line. The role HIF-1 plays in the survival 
signaling of both cell lines remains to be fully elucidated and is currently 
under investigation. 
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UP-REGULATION OF THE p75 DEATH RECEPTOR FOLLOWING 
EXPOSURE OF ESFT CELLS TO bFGF. 
Jim Boyne*, Ben Dibling and Susan Burchill.   
Candlelighter’s Children’s Cancer Research Laboratory, Cancer Research 
UK Clinical Centre, St James's University Hospital, Leeds, LS9 7TF, UK.  
 
Our previous experiments have shown that treatment of tumours of the 
Ewing’s sarcoma family (ESFTs) with basic fibroblast growth factor (bFGF)-
induces cell death (Sturla et al, 2000, Cancer Research, 60(1), 6160-6170). 
bFGF-induced cell death is associated with activation of the initiator caspases 
-2, -8 and –10 (Westwood et al, 2002, Oncogene, 21(5):809-824), which are 
most frequently cleaved by members of the TNF super-family of receptors. In 
this study we have investigated the hypothesis that bFGF-induced cell death 
may be mediated through the cell death receptor p75.  
The effect of bFGF (20ng/ml) has been examined in 6 ESFT cell lines. 
Phosphorylation of FGFR1 and activation of the downstream signalling 
molecules Ras and ERK was investigated by immunoprecipitation, GST 
binding assay and Western blot respectively. The effect of bFGF on p75 
expression was also determined by Western blot. 
bFGF induced cell death in 4/6 cell lines studied and was independent of 
EWS-ETS gene rearrangement type. Phosphorylation of FGFR1 was observed 
within a 5 min exposure of ESFT cells to bFGF. This was accompanied by 
phosphorylation of a co-precipitated protein (90kD), consistent with that of 
the FGF docking protein FRS2, and activation of the downstream signalling 
molecules Ras and ERK. Up-regulation of the death receptor p75 occurred 
24h after exposure to bFGF in ESFT cells, this preceded cleavage of caspases 
–2, -8 and –10 (48h) and cell death (48-72h) (Westwood et al, as above). 
However expression of p75 was unchanged in ESFT cells that do not die 
when exposed to bFGF. 
In summary, bFGF-induced cell death appears to be initiated by 
phosphorylation of FGFR1 and rapid activation of the downstream signalling 
proteins Ras and ERK. This precedes up-regulation of the death receptor p75, 
which may be transcriptionally regulated by bFGF. These data are consistent 
with an ordered cell death pathway, which could offer novel targets in the 
development of therapeutic treatments for ESFTs. 
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ANGIOGENESIS IN ANAL WARTS, ANAL INTRAEPITHELIAL 
NEOPLASIA (AIN) AND ANAL SQUAMOUS CELL CARCINOMA 
*J. Mullerat
1, L.F. Wong Te Fong
2, S. E. Davies
3, M.C.
 Winslet
1, C.W.
 
Perrett
2 
Departments of 
1Surgery, 
2Obstetrics and Gynaecology, 
3Histopathology, 
Royal Free campus, Royal Free and University College Medical School, 
London, U.K. 
 
Introduction: 
Squamous cell carcinoma (SCC) of the anus is a rare malignancy, but it is 
becoming increasingly more common. Most cases of anal carcinoma seem to 
develop from dysplastic anal lesions (anal intraepithelial neoplasia - AIN) 
caused by persistent anal warts. In this study we examined biopsies of anal 
lesions ranging from warts to invasive anal carcinoma, with the aim to 
compare the degree of angiogenesis between anal warts, AIN and anal SCC. 
Method: 
Samples from 70 patients (56 males and 18 females) who had undergone 
excision biopsy or resection of anal warts (20), AIN I (12), AIN II-III (25) 
and anal SCC (13) were studied. The samples were stained for von 
Willebrand factor (vWF), a specific marker of endothelial cells. Angiogenesis 
was measured by microvessel density (MVD), quantifying the microvessels 
in the stroma adjacent to the epithelial lesion, by 3 different observers.  
Results: 
Average microvessel counts and standard deviation values were as follows: 
6.30  2.50 for warts; 8.34  2.83 for low-grade AIN; 16.28  3.92 for high-
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significant increase (p<0.001) in MVD in high grade anal intraepithelial 
neoplasia (AIN II-III) compared to low grade anal intraepithelial neoplasia 
(AIN I) and in anal SCC compared to AIN II-III. 
Conclusion: 
There is increased angiogenesis in in high grade AIN, compared to low grade 
AIN and anal warts. These findings suggest that there are progressive 
abnormal patterns of microvascularisation at early stages of anal 
carcinogenesis. 
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HOW ACCURATELY CAN THE ONCOLOGIST REPORT FDG-PET 
TUMOUR RESPONSE USING THE ADAC VERTEX PLUS DUAL-
HEADED GAMMA CAMERA?  
RL Bowen*
1, RJ Francis
1, AJ Green
1, S Baig
1, V Knell
1, JR Buscombe
2, 
AJW Hilson
2, RHJ Begent
1 
1CRC Targeting and Imaging Group, Department of Oncology, Royal Free 
Campus, Royal Free & University College Medical School, UCL, London, 
NW3 2PF 
2Department of Nuclear Medicine, Royal Free Hospital, London, NW3 2PF 
 
Purpose: We compared the visual reports of two experienced Nuclear 
Medicine Consultants and those of an oncology research fellow with no 
previous FDG-PET experience and minimal training, to assess whether this 
method of detecting tumour response can be reliably reported by the 
oncologist.  
Methods: Twenty-two patients with unresectable, locally recurrent or 
metastatic colorectal, oesophageal, hepatocellular, pancreatic and breast 
carcinoma receiving conventional chemotherapy were assessed with FDG-
PET scans at 0, 2-4 and 8-12 weeks. FDG-PET scans were performed on an 
ADAC Vertex Plus Dual Headed Gamma Camera.  Twenty one pairs of 
scans were assigned random numbers and temporal order and the three 
investigators were required to report stable disease, response or progressive 
disease while blinded to the patient details, the natural order of the scans and 
the CT and tumour marker responses.  The actual tumour response at each 
time point was determined by combining FDG-PET appearances, CT scan 
and tumour marker responses and patient follow-up. 
Results: Both experts reported the scans accurately in 76% and the novice 
reported the correct FDG-PET response in 81% of cases.  The nuclear 
medicine physicians concurred with each other in 76% of cases although they 
were not always accurate in the same scan pairs.  The novice concurred with 
both nuclear medicine physicians in 62% (13/21) of cases. Of these 13 scan 
pairs the accurate report differed in only one.  In one partial response all three 
investigators reported stable disease.  Where there was no concordance with 
the experts the novice was correct in 63%(5/8).  At least one of the experts 
reported accurately in 100% (3/3) of the scan pairs where the novice was 
incorrect. 
Conclusion: Our results confirm that FDG-PET is a robust technique for 
assessing tumour response to chemotherapy.  This could have wide reaching 
benefits for cancer centres and units where the more affordable Dual-Headed 
Gamma Camera could be used routinely.  Report reliability may be further 
improved with the use of a method for quantitatively assessing tumour uptake 
of FDG and therefore response.   
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PHAGE DERIVED-ANTI-VEGF-RECEPTOR-2 (VEGF-R2) 
ANTIBODY IN COMBINATION WITH METRONOMIC 
ESTRAMUSTINE : A NOVEL STRATEGY FOR INHIBITING 
ANGIOGENESIS 
T. Lam*
1, J. Greenman
1, C. Newton
1, J. Hetherington
2 & A. Maraveyas
2  
1Medical Research Laboratory, University of Hull, Hull HU6 7RX;  
2Academic Department of Uro-oncology, Princess Royal Hospital, Hull HU8 
9HE. 
 
VEGF-receptor-2 has been proposed as a rational target of anti-angiogenic 
therapy, due to its fundamental role in mediating the mitogenic effects of 
VEGF on vascular endothelial cells.  Metronomic dosing is a new approach 
in the treatment of cancer whereby low concentrations of cytotoxic drugs 
with strong anti-angiogenic actions are given continuously in combination 
with an anti-angiogenic biological agent to optimize inhibition of 
angiogenesis whilst minimizing systemic toxicity. However, the ideal agents 
for such a therapeutic strategy remain unclear.  
We are in the process of developing a novel anti-angiogenic treatment 
strategy combining an anti-VEGF-R2 blocking antibody derived from phage 
display technology with metronomic dosing of estramustine, an orally 
bioavailable cytotoxic agent with anti-mitotic actions. 
Single-chain antibodies specific for VEGF-R2 were isolated using a phage 
display library after 5 rounds of biopanning against recombinant VEGF-
R2/Fc chimera immobilized on immunotubes, and against the same antigen 
suspended in solution coupled to magnetic beads. Further selection  is being 
performed using ELISA, with VEGF-R1 as negative control, and through 
competitive binding with VEGF, hence selecting a VEGF-R2 specific 
antibody capable of blocking the binding of VEGF to VEGF-R2. Endothelial 
cytotoxicity of the blocking antibody and estramustine is being assessed 
using a human umbilical vein endothelial cell culture model, with growth 
(cell count and DNA replication), biological (formation of vascular networks 
and changes in VEGF-R2 activation) and survival (DNA fragmentation 
ELISA) parameters being determined as end-points. 
The combination of metronomic dosing of estramustine with an anti-VEGF-
R2  blocking  antibody represents a new and potentially powerful anti-
angiogenic treatment strategy.  Benefits include high efficacy of anti-
angiogenic effect due to the postulated synergy between the two agents based 
on enhancing endothelial cell apoptosis, high specificity due to the targeted 
action of the blocking antibody, ease of administration of estramustine (oral) 
and possibly low systemic toxicity due to the use of low doses of both agents.  
This approach is likely to have future implications for the treatment of 
traditionally chemo-resistant and highly vascular tumours such as advanced 
renal cell carcinoma. 
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COMPARISON OF THE THERAPEUTIC RESPONSE IN 
LEUKAEMIC GUINEA PIGS BETWEEN MODULATING AND NON-
MODULATING ANTIBODY DERIVATIVES 
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1Tenovus Research Laboratory, 
Southampton University Hospital, Tremona Road, Southampton SO16 6YD. 
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A murine monoclonal antibody, 5G10, has been raised against the strain 2 
guinea pig lymphocytes in the Institute of Tenovus. Using indirect flow 
cytofluorimetric analysis, 5G10 IgG antibody was found to remain on the 
surface of target cells over a two-hour incubation period. On the contrary, the 
% of initial fluorescence of a modulating monoclonal antibody, RJD IgG, 
was found to decline dramatically over the same incubation period. This 
shows that bound 5G10 IgG antibody is not internalised by the target cells.  
The therapeutic response in leukaemic strain 2 guinea pigs was compared 
between the 5G10 non-modulating antibody derivatives and RJD modulating 
antibody derivatives. In this study, mouse/human chimeric antibody 
derivatives were synthesised in which the Fc  is of human origin. Two types 
of antibody constructs, namely univalent FabFc2 and bivalent Fab2Fc2, were 
produced from both 5G10 and RJD. In the therapy, groups of 10 age-matched 
guinea pigs were inoculated i.p. with 5 x 10
4 L2C leukaemic cells. 24 hours 
after the inoculation, 4 mg of one of the four antibody derivatives was 
injected i.v. into each animal and their survival over 30 days was recorded. 
5G10 bivalent Fab2Fc2 showed a significant therapeutic response whereas 
5G10 univalent FabFc2 produced no therapeutic effects. On the contrary, RJD 
univalent FabFc2 showed much better therapeutic results over the RJD 
bivalent Fab2Fc2. These observations show that therapeutically, bivalent 
antibody constructs derived from non-modulating antibodies outperform the 
equivalent univalent constructs. On the contrary, univalent constructs derived 
from modulating-antibodies outperform the corresponding bivalent 
derivatives. Therefore, when designing antibody constructs for cancer 
immunotherapy, these are the important factors to consider.  
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PROFILING PROTEINS IN CELLS AFTER TREATMENT WITH 5-
AZA-2 DEOXYCYTIDINE (DECITABINE)  
Debra Stuart*, Chris Twelves, and Robert Brown.  
Department of Medical Oncology, Alexander Stone Building, Garscube 
Estate, Switchback Road, Bearsden, Glasgow University, Glasgow, UK 
  
The DNA methyl transferase inhibitor 5-aza-2-deoxycytidine (Decitabine) 
can sensitise ovarian and colon tumour cell xenografts to a number of 
chemotherapeutic agents by demethylating DNA and reversing gene 
promoter methylation (Plumb, et al Cancer Res 60:21 6039-6044, 2000). This 
sensitivity correlates with re-expression of the mismatch repair protein 
hMLH1. Treatment of the cisplatin resistant human ovarian cell line 
A2780/cp70 for 24hrs with 1M Decitabine induces the expression of a 
number of previously unexpressed gene products, including  hMLH1, after 7 
days in culture. Using two dimensional electrophoresis we have identified 31 
distinct protein spots that are consistently present in cells exposed to 
Decitabine, but absent in control treated cells. In  comparison, we have 
identified 15 protein spots present in control cells but lost from cells after 
treatment with Decitabine. Matrix Assisted Laser Desorption Mass 
Specrometry (MALDI-MS) and immunoblotting are being used to further 
characterise the protein changes induced by Decitabine in A2780/cp70.    
Decitabine is currently being evaluated as an anti-cancer agent in clinical 
trials, both alone, and in combination with other therapeutic agents. Changes 
in protein expression have been analysed in peripheral blood mononuclear 
cells and skin samples from mice pre and post treatment with Decitabine. 
Results suggest analysis of these tissues may be an effective way of 
monitoring protein changes after exposure of cells in vivo to Decitabine. 
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TELOMERASE-DIRECTED GENE THERAPY OF HUMAN CANCER 
CELLS USING  THE BACTERIAL NITROREDUCTASE GENE. 
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Re-activation of human telomerase activity maintains telomere function, 
compensating for cell-division associated telomere attrition and is considered 
an essential late stage in immortalisation of human tumour cells. Since the 
association of human telomerase activity with cancer cells is highly specific 
and the RNA (hTERC) and protein (hTERT) components of telomerase are 
differentially regulated on a transcriptional level between normal and cancer 
cells, telomerase promoters may be useful in targeted gene therapy for the 
treatment of human malignancy. We used hTERC and hTERT promoter 
luciferase-reporters to quantify promoter activities in a panel of normal, 
cancer and ALT cell lines derived from lung, ovary, cervix, bladder and 
colon. Large differences were observed in promoter activities between 
normal and cancer cells, with all cancer cell lines tested showing higher 
promoter activity than the mortal cell strains tested. These differences were in 
the range of 40-300-fold for the hTERC promoter, while the hTERT 
promoter had a high activity in several cancer cell lines (29-833 light units) 
but did not appear above background in the mortal cell strains. We therefore 
selected a number of high and low expressing cell lines for inclusion in a 
stable cell line model of telomerase directed suicide gene therapy using the 
bacterial nitroreductase (NTR) gene which converts the pro-drug CB1954 to 
a cytotoxic form. We used MTT assay to quantify the IC50 value for the 
cytotoxic effect of CB1954 on cell lines harbouring hTERC-NTR, hTERT-
NTR, CMV-NTR and promoter-less NTR constructs. The telomerase 
promoters could drive sufficient NTR expression to sensitise five human 
cancer cell lines with high promoter activity to the effects of bio-activated 
CB1954. In sensitive cell lines, the hTERC-NTR construct resulted in a range 
of sensitisation between 6-fold (lung adenocarcinoma cells) and 19-fold 
(ovarian adenocarcinoma cells) and the hTERT-NTR construct resulted in 
fold-sensitisation values between 5-fold (ovarian adenocarcinoma) and 14-
fold (colorectal adenocarcinoma cells). The effect was dependent on high 
promoter activity and correlated with northern blots for NTR. We next 
addressed whether the vectors could sensitise cancer cells to CB1954 in vivo. 
Xenograft models of telomerase-NTR, CMV-NTR and negative control 
stable cell line sets of small cell lung cancer and cervical carcinoma cells 
were established and mice bearing tumours were given a single tail-vein 
injection of 40 or 80mg/kg CB1954. Tumour volumes were monitored for 7 
days. hTERC- and hTERT-NTR tumours showed 63% and 76% reduction in 
the cervical model and 90% and 97% reduction in the lung model. Thus, 
telomerase directed gene therapy is an attractive approach for further 
development. 
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DESIGN, SYNTHESIS AND EVALUATION OF A  STRUCTURALLY 
NEW CLASS OF TOPOISOMERASE I INHIBITORS: OXA-AZA-
BENZO[de]ANTHRACENES 
A Di Salvo*, G Barsacq, D J Mincher, G Kay, Anticancer Drug Design and 
Delivery Research Group, School of Life Sciences, Napier University, 
Edinburgh, EH10 5DT, UK. 
 
Human DNA topoisomerase I has been shown to be a valid target for 
anticancer therapy and inhibitors of this enzyme include the clinically active 
camptothecin derivatives topotecan and irinotecan. The clinical effectiveness 
of the camptothecin class of compounds is limited by the rapid in vivo 
conversion to inactive metabolites as a result of inherently labile structural 
features of the active drug molecules
1.  
Towards the design of non-camptothecin inhibitors of topo I with increased 
structural stability we report the rational design and synthesis of a series of 
oxa-aza-benzo[de]anthracenes with angular ring systems that possess limited 
ability to intercalate into DNA and have enhanced DNA groove binding 
capability: features that favour interaction with topoisomerase I. 
 
NO
O
OH
O
O
NH3
R
(1) R = CH3
(2) R = CH2Ph
OOC CF3 .
 
The 2H-3-oxa-1-aza-benzo[de]anthracen-7-ones  (1) and (2) are 
representatives of a new class of topo I inhibitor with cytotoxic activity 
against human and animal cell lines in vitro; for example the L-alanine 
conjugate (1) is active against the human leukaemic HL60 cell line (IC50 
7M) and completely inhibited the topo I-mediated relaxation of supercoiled 
pBR322 DNA at 50M as shown by changes in the electrophoretic mobility 
of the plasmid in vitro. 
The chemosensitivity and enzyme inhibitory properties are modulated by the 
nature of the amino acid side-chain (R-group). Correlations are drawn 
between chemical structure, cytotoxic potency, DNA binding and 
topoisomerase I inhibition for this novel class of inhibitor that lacks the 
structural lability of the camptothecins.   
1 Y. Pommier, (1998), Biochimie, 80, 255. 
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INTERACTION BETWEEN SN-38 AND 5-FLUOROURACIL (5-FU) 
IN RENAL CANCER CELL LINES  
V Sayer, N Darvill, S Joel, T Oliver, J Shamash. Dept Medical Oncology, St 
Bartholomew’s Hospital, London. 
 
Although renal tumours generally have low sensitivity to conventional 
cytotoxic agents, 2 of the most active drugs are 5-FU and Irinotecan. Recent 
data suggests that 5-FU and SN-38, the active metabolite of Irinotecan, are 
synergistic in colorectal cancer cell lines when SN-38 is followed by 5-FU 
(Pavillard et al, Biochem Pharm 1998, 56(10):1315-22).  We have therefore 
investigated the activity of 5-FU/SN-38 combinations in a panel of renal 
cancer cell lines (RCC 39, RCC42, RCC45, kindly provided by Dr Terry 
Rabbits, MRC, Cambridge), focussing particularly on the effect of sequence 
of exposure. Firstly, the EC50 (% viability, (%V)) for each drug in each cell 
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